Recent Finacing
Recent Raise
Corvus Pharmaceuticals develops small-molecule and antibody immuno-oncology therapies that modulate immune checkpoints and reprogram T cells, with an oral checkpoint inhibitor entering Phase 1b trials.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at Corvus Pharmaceuticals.
